

**Supplementary Table 1.** Statistical analysis of reactogenicity data between booster vaccines.

|                            | Total      | BBIBP     | AZD1222   | BNT162b2  | mRNA-<br>1273 | Pearson's<br>$\chi^2$ | Pair-wise analysis (Fisher's Exact test) |         |         |        |        |        |  |
|----------------------------|------------|-----------|-----------|-----------|---------------|-----------------------|--|---------|---------|--------|--------|--------|--|
|                            |            |           |           |           |               |                       | 1 vs 2                                   | 1 vs 3  | 1 vs 4  | 2 vs 3 | 2 vs 4 | 3 vs 4 |  |
| <b>N (%)</b>               | 224 (100)  | 57 (100)  | 55 (100)  | 54 (100)  | 58 (100)      |                       |  |         |         |        |        |        |  |
| <b>Injection site pain</b> | 187 (83.5) | 34 (59.6) | 46 (83.6) | 52 (96.3) | 55 (94.8)     | < 0.001               | 0.006                                    | < 0.001 | < 0.001 | 0.052  | 0.069  | 1.000  |  |
| <b>Swelling</b>            | 71 (31.7)  | 2 (3.5)   | 19 (34.5) | 16 (29.6) | 34 (58.6)     | < 0.001               | < 0.001                                  | < 0.001 | < 0.001 | 0.683  | 0.010  | 0.002  |  |
| <b>Redness</b>             | 63 (28.1)  | 6 (13.7)  | 16 (29.1) | 18 (33.3) | 23 (39.7)     | 0.004                 | 0.017                                    | 0.005   | < 0.001 | 0.683  | 0.322  | 0.558  |  |
| <b>Fever</b>               | 11 (4.9)   | 0 (0.0)   | 5 (9.1)   | 2 (3.7)   | 4 (6.9)       | 0.046 <sup>a</sup>    | 0.026                                    | 0.234   | 0.119   | 0.438  | 0.738  | 0.680  |  |
| <b>Headache</b>            | 120 (53.6) | 28 (49.1) | 34 (61.8) | 20 (37.0) | 38 (65.5)     | 0.011                 | 0.189                                    | 0.251   | 0.091   | 0.013  | 0.700  | 0.004  |  |
| <b>Myalgia</b>             | 148 (66.1) | 24 (42.1) | 41 (74.5) | 38 (70.4) | 45 (77.6)     | < 0.001               | 0.001                                    | 0.004   | < 0.001 | 0.672  | 0.826  | 0.398  |  |
| <b>Nausea</b>              | 37 (16.5)  | 9 (15.8)  | 11 (20.0) | 7 (13.0)  | 10 (17.2)     | 0.796                 | 0.627                                    | 0.789   | 1.000   | 0.440  | 0.810  | 0.604  |  |
| <b>Vomiting</b>            | 6 (2.7)    | 0 (0.0)   | 0 (0.0)   | 2 (3.7)   | 4 (6.9)       | 0.029 <sup>a</sup>    | N/A                                      | 0.234   | 0.119   | 0.243  | 0.119  | 0.680  |  |
| <b>Diarrhoea</b>           | 32 (14.3)  | 6 (10.5)  | 12 (21.8) | 4 (7.4)   | 10 (17.2)     | 0.127                 | 0.127                                    | 0.743   | 0.420   | 0.056  | 0.637  | 0.155  |  |
| <b>Joint pain</b>          | 53 (23.7)  | 7 (12.3)  | 19 (34.5) | 7 (13.0)  | 20 (34.5)     | 0.002                 | 0.007                                    | 1.000   | 0.008   | 0.013  | 1.000  | 0.009  |  |
| <b>Chilling</b>            | 101 (45.1) | 9 (15.8)  | 32 (58.2) | 20 (37.0) | 40 (69.0)     | < 0.001               | < 0.001                                  | 0.017   | < 0.001 | 0.035  | 0.248  | 0.001  |  |
| <b>Dizziness</b>           | 67 (39.9)  | 13 (22.8) | 17 (30.9) | 14 (25.9) | 23 (49.7)     | 0.218                 | 0.396                                    | 0.825   | 0.070   | 0.672  | 0.431  | 0.160  |  |

<sup>a</sup> Likelihood Ratio is applied due to expected cell count less than 5 more than 20% of cells

**Supplementary Table 2.** The value and statistical analysis of GMT (with 95% confidence intervals) of total RBD Ig and anti-RBD IgG, median (with interquartile ranges) of anti-N IgG.

|  | BBIBP<br>(I)                 | AZD1222<br>(II)                 | BNT162b2<br>(III)               | mRNA-1273<br>(IV)               | Total                           | Kruskal-<br>Wallis | Pair-wise analysis (Mann Whitney) |              |             |               |                      |               |
|--|------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------|-----------------------------------|--------------|-------------|---------------|----------------------|---------------|
|  |                              |                                 |                                 |                                 |                                 |                    | (I) vs (II)                       | (I) vs (III) | (I) vs (IV) | (II) vs (III) | (II) vs (IV)         | (III) vs (IV) |
| <b>SARS-CoV-2 total RBD Ig, (U/ml), GMT 95% CI]</b>    |                              |                                 |                                 |                                 |                                 |                    |                                   |              |             |               |                      |               |
| <b>Day 0</b>   | 46.01<br>(33.87-62.50)       | 35.17<br>(27.32-45.26)          | 41.67<br>(31.38-55.32)          | 27.07<br>(20.44-35.84)          | 36.49<br>(31.72-41.97)          | 0.033 <sup>a</sup> | 1.000                             | 1.000        | 0.035       | 1.000         | 1.000 <sup>b</sup>   | 0.156         |
| <b>Day 14</b>  | 1740.00<br>(1443.81-2096.95) | 12259.51<br>(10333.78-14544.10) | 31792.88<br>(27428.26-36852.03) | 51979.58<br>(43920.69-61516.02) | 13650.90<br>(11269.99-16534.79) | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | < 0.001       | < 0.001 <sup>b</sup> | 0.099         |
| <b>Day 28</b>  | 1294.54<br>(1084.08-1545.87) | 12111.12<br>(10153.22-14446.57) | 21053.33<br>(18145.07-24427.73) | 33519.20<br>(28228.32-39802.45) | 10146.77<br>(8426.09-12218.84)  | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | 0.017         | < 0.001 <sup>b</sup> | 0.085         |
| <b>SARS-CoV-2 anti-RBD IgG, (BAU/ml), GMT [95% CI]</b> |                              |                                 |                                 |                                 |                                 |                    |                                   |              |             |               |                      |               |
| <b>Day 0</b>   | 23.16<br>(17.83-30.08)       | 17.55<br>(14.52-21.23)          | 26.01<br>(21.16-31.97)          | 18.13<br>(14.78-22.23)          | 20.85<br>(18.71-23.23)          | 0.028 <sup>a</sup> | 0.435                             | 1.000        | 0.609       | 0.073         | 1.000 <sup>b</sup>   | 0.109         |
| <b>Day 14</b>  | 212.55<br>(175.84-256.93)    | 2226.68<br>(1858.02-2668.49)    | 4877.73<br>(4221.82-5635.55)    | 8901.15<br>(7471.96-10605.14)   | 2120.51<br>(1723.96-2608.29)    | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | 0.001         | < 0.001 <sup>b</sup> | 0.017         |
| <b>Day 28</b>  | 183.83<br>(153.94-219.51)    | 1808.49<br>(1528.28-2140.07)    | 3836.95<br>(3292.30-4471.70)    | 6846.00<br>(5867.92-7987.17)    | 1702.33<br>(1393.57-2079.51)    | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | 0.002         | < 0.001 <sup>b</sup> | 0.012         |
| <b>SARS-CoV-2 anti-N IgG, (S/C), median [IQR]</b>      |                              |                                 |                                 |                                 |                                 |                    |                                   |              |             |               |                      |               |
| <b>Day 0</b>   | 0.16<br>(0.08-0.32)          | 0.12<br>(0.05-0.26)             | 0.15<br>(0.10-0.36)             | 0.13<br>(0.07-0.33)             | 0.13<br>(0.07-0.31)             | 0.251              | ns                                | ns           | ns          | ns            | ns                   | ns            |
| <b>Day 14</b>  | 2.78<br>(1.84-5.30)          | 0.12<br>(0.05-0.27)             | 0.14<br>(0.09-0.41)             | 0.14<br>(0.09-0.37)             | 0.24<br>(0.09-1.13)             | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | 1.000         | 1.000                | 1.000         |
| <b>Day 28</b>  | 2.89<br>(1.55-4.87)          | 0.10<br>(0.06-0.23)             | 0.12<br>(0.08-0.31)             | 0.12<br>(0.07-0.31)             | 0.19<br>(0.08-1.02)             | < 0.001            | < 0.001                           | < 0.001      | < 0.001     | 1.000         | 1.000 <sup>b</sup>   | 1.000         |

<sup>a</sup> tested using student's t-test; tests were adjusted by Bonferroni correction for multiple tests.

<sup>b</sup> adjusted for age


**Supplementary Table 3.** The percentage inhibition against wild-type and SARS-CoV-2 variants.

|  | <b>BBIBP (I)</b>    | <b>AZD1222 (II)</b> | <b>BNT162b2 (III)</b> | <b>mRNA-1273 (IV)</b> |
|--|---------------------|---------------------|-----------------------|-----------------------|
| <b>sVNT—Wild Type. (GenScript), median (IQR)</b> |                     |                     |                       |                       |
| Day 0  | 20.50 (13.60-32.00) | 15.45 (11.20-24.38) | 20.15 (8.075-30.55)   | 7.250 (1.20-17.00)    |
| Day 28   | 87.55 (72.58-96.63) | 97.30 (97.10-97.50) | 97.50 (97.30-97.50)   | 98.30 (98.30-98.40)   |
| <b>sVNT—Alpha. (GenScript), median (IQR)</b>     |                     |                     |                       |                       |
| Day 0  | 22.0 (14.4-29.2)    | 20.6 (15.5-23.6)    | 23.8 (15.8-27.0)      | 5.10 (0.075-8.48)     |
| Day 28   | 75.4 (55.8-92.4)    | 97.9 (97.5-98.3)    | 98.1 (97.9-98.3)      | 98.2 (98.2-98.3)      |
| <b>sVNT—Beta. (GenScript), median (IQR)</b>      |                     |                     |                       |                       |
| Day 0  | 8.65 (3.75-23.9)    | 9.20 (5.35-12.5)    | 9.20 (5.35-12.5)      | 13.5 (6.50-18.9)      |
| Day 28   | 68.7 (44.5-84.6)    | 96.0 (94.2-96.8)    | 96.0 (94.2-96.8)      | 98.0 (97.6-98.2)      |
| <b>sVNT—Delta. (GenScript), median (IQR)</b>     |                     |                     |                       |                       |
| Day 0  | 18.4 (14.1-37.8)    | 14.8 (12.6-21.8)    | 22.7 (10.2-31.2)      | 19.1 (9.80-24.0)      |
| Day 28   | 86.0 (69.6-94.8)    | 97.5 (97.3-97.6)    | 97.5 (97.3-97.6)      | 98.2 (98.2-98.3)      |
| <b>sVNT—Omicron. (GenScript), median (IQR)</b>   |                     |                     |                       |                       |
| Day 0  | 6.70 (4.18-8.88)    | 4.05 (2.45-6.68)    | 5.50 (1.85 -8.55)     | 5.35 (3.93-12.7)      |
| Day 28   | 9.00 (0.00-17.7)    | 45.3 (26.5-76.2)    | 53.5 (26.3-70.0)      | 76.7 (60.6-91.6)      |


**Supplementary Table 4.** The IFN- $\gamma$  CD4+/IFN- $\gamma$  CD4+ and CD8+ levels

|   | <b>BBIBP (I)</b>  | <b>AZD1222 (II)</b> | <b>BNT162b2 (III)</b> | <b>mRNA-1273 (IV)</b> |
|---|-------------------|---------------------|-----------------------|-----------------------|
| <b>IFN-<math>\gamma</math> CD4+ T-cell (IU/ml), median (IQR)</b>      |                   |                     |                       |                       |
| Day 0   | 0.04 (0.00-0.155) | 0.05 (0.01-0.22)    | 0.05 (0.01-0.19)      | 0.03 (0.01-0.20)      |
| Day 14  | 0.09 (0.01-0.38)  | 0.18 (0.53-1.60)    | 1.12 (0.41-2.22)      | 0.9 (0.25-1.78)       |
| Day 28  | 0.14 (0.02-0.25)  | 0.30 (0.13-0.90)    | 0.74 (0.20-1.46)      | 0.77 (0.26-1.83)      |
| <b>IFN-<math>\gamma</math> CD4+/CD8+ T-cell (IU/ml), median (IQR)</b> |                   |                     |                       |                       |
| Day 0   | 0.06 (0.01-0.198) | 0.12 (0.03-0.25)    | 0.10 (0.02-0.23)      | 0.11 (0.00-0.31)      |
| Day 14  | 0.12 (0.05-0.43)  | 0.88 (0.48-2.32)    | 2.22 (0.82-2.70)      | 1.68 (0.39-2.68)      |
| Day 28  | 0.16 (0.02-0.35)  | 0.48 (0.29-1.21)    | 1.02 (0.37-2.40)      | 1.03 (0.40-2.31)      |


Supplementary Figure 1. Participant flow chart in the heterologous booster cohorts.




A



B




C



**Supplementary Figure 2.** Forest plot presents any grade the solicited local and systemic adverse events (AEs) across 7 days post-boost vaccination and the absolute risk differences comparison between BBIBP to AZD1222, BNT162b2, and mRNA1273 in the proportion of participants with 95% confidence intervals.

# Alpha



**Supplement Figure 3.** The neutralizing activities against alpha variant. Each data point is represented of the individual who received a heterologous third booster vaccine, the inactivated vaccine, BBIBP (green), the viral-vector vaccine, AZD1222 (orange), the mRNA vaccine, BNT162b2 (blue), or mRNA-1273 (gold). Lines represent median (IQR). ns indicates no significant difference;  $p < 0.01$  (\*\*),  $p < 0.001$  (\*\*\*).